Hims & Hers Health, Inc. (NYSE:HIMS) Receives Consensus Rating of “Hold” from Analysts

Hims & Hers Health, Inc. (NYSE:HIMS) has been given an average recommendation of “Hold” by the fifteen research firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $37.23.

A number of research analysts recently weighed in on the company. Piper Sandler lifted their target price on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday. Leerink Partners lifted their target price on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a report on Tuesday. Needham & Company LLC lifted their target price on Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday. Deutsche Bank Aktiengesellschaft lifted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Finally, Canaccord Genuity Group lifted their target price on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th.

Hims & Hers Health Stock Up 9.3 %

HIMS stock opened at $45.20 on Friday. Hims & Hers Health has a 52-week low of $11.20 and a 52-week high of $72.98. The stock’s fifty day simple moving average is $36.57 and its 200-day simple moving average is $26.66. The stock has a market capitalization of $9.87 billion, a price-to-earnings ratio of 102.72 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. As a group, analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Michael Chi sold 2,054 shares of Hims & Hers Health stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $33.56, for a total transaction of $68,932.24. Following the sale, the insider now directly owns 184,947 shares of the company’s stock, valued at approximately $6,206,821.32. The trade was a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $24.44, for a total value of $283,039.64. Following the sale, the chief financial officer now directly owns 118,077 shares in the company, valued at approximately $2,885,801.88. The trade was a 8.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,097,578 shares of company stock valued at $38,080,320 over the last three months. 17.71% of the stock is owned by company insiders.

Institutional Trading of Hims & Hers Health

Hedge funds and other institutional investors have recently modified their holdings of the business. Main Management ETF Advisors LLC purchased a new stake in shares of Hims & Hers Health during the third quarter worth about $672,000. Robeco Institutional Asset Management B.V. purchased a new stake in shares of Hims & Hers Health during the third quarter worth about $604,000. Royce & Associates LP increased its holdings in Hims & Hers Health by 17.0% in the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock valued at $6,281,000 after buying an additional 49,500 shares during the last quarter. Versor Investments LP bought a new stake in Hims & Hers Health in the third quarter valued at about $634,000. Finally, International Assets Investment Management LLC bought a new stake in Hims & Hers Health in the third quarter valued at about $6,790,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.